LABORATORY RESEARCH
HER2 Overexpression Elicits a Pro-Inflammatory IL-6 Autocrine Signaling Loop that Is Critical for Tumorigenesis In this study, scientists explore the relationship between HER2 and inflammation, comparing the effects of overexpressing wild-type or mutated inactive forms of HER2 in primary human breast cells. [Cancer Res]
Proangiogenic Factor PlGF Programs CD11b+ Myelomonocytes in Breast Cancer During Differentiation of Their Hematopoietic Progenitors Researchers show that CD11b+ myelomonocytic cells develop proangiogenic properties during their differentiation from CD34+ hematopoietic progenitors and that placenta growth factor (PIGF) is critical in promoting this education. [Cancer Res]
Inhibition of PDE5 by Sulindac Sulfide Selectively Induces Apoptosis and Attenuates Oncogenic Wnt/Beta-Catenin Mediated Transcription in Human Breast Tumor Cells Investigators show that sulindac sulfide can induce apoptosis of breast tumor cells, which predominantly rely on phosphodiesterase 5 (PDE5) for cGMP hydrolysis, but not normal mammary epithelial cells, which rely on PDE isozymes other than PDE5 for cGMP hydrolysis. [Cancer Prev Res]
mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients Scientists determined mRNA and microRNA expression of potentially circulating tumor cell-specific genes that are considered to be clinically relevant in breast cancer. [Clin Cancer Res]
Novel Measurements of Mammary Stem Cells in Human Umbilical Cord Blood as Prospective Predictors of Breast Cancer Susceptibility in Later Life Investigators isolated mononuclear cells from umbilical cord blood of 170 singleton full-term pregnancies and determined, by reverse transcription polymerase chain reaction, the presence of genes of putative breast epithelial stem-cell/progenitor markers [including epithelial cell adhesion molecule, CD49f (a6-integrin), CD117 (c-kit receptor), CD24, and CD29 (ß1-integrin)]. [Ann Oncol] ATM and p53 Regulate FOXM1 Expression Via E2F in Breast Cancer Epirubicin Treatment and Resistance Researchers generated epirubicin resistant MCF-7 breast carcinoma (MCF-7-EPIR) cells and found FOXM1 protein levels to be higher in MCF-7-EPIR compared to MCF-7 cells, and that FOXM1 expression is down-regulated by epirubicin in MCF-7 but not in MCF-7-EPIR cells. [Mol Cancer Ther]
B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation Investigators observed that silencing B7-H3, via stable shRNA or transient siRNA transfection, increased the sensitivity of multiple human breast cancer cell lines to paclitaxel as a result of enhanced drug-induced apoptosis. [Mol Cancer Ther]
Targeting GLI1 Expression in Human Inflammatory Breast Cancer Cells Enhances Apoptosis and Attenuates Migration Data reveal a role for GLI1 in inflammatory breast cancer (IBC) cell proliferation, survival and migration, which supports the feasibility of targeting GLI1 as a novel therapeutic strategy for IBC patients. [Br J Cancer]
Elevated Expression of Squamous Cell Carcinoma Antigen (SCCA) Is Associated with Human Breast Carcinoma This study shows that SCCA is associated with both advanced stage and high grade human breast carcinoma, and suggests the necessity to further explore the role of SCCA in breast cancer development and treatment. [PLoS One]
Molecular Profiling of a Lethal Tumor Microenvironment, as Defined by Stromal Caveolin-1 Status in Breast Cancers To identify and characterize the signaling pathways activated in caveolin-1 negative tumor stroma, researchers performed gene expression profiling using laser microdissected breast cancer associated stroma. [Cell Cycle]
CLINICAL RESEARCH
Use of Tamoxifen and Aromatase Inhibitors in a Large Population-Based Cohort of Women with Breast Cancer Scientists constituted a cohort of 13?479 women with breast cancer who received at least one prescription of tamoxifen or aromatase inhibitors between 1998 and 2008, in the United Kingdom General Practice Research Database. [Br J Cancer]
Trastuzumab Beyond Progression in HER2-Positive Advanced Breast Cancer: The Royal Marsden Experience Investigators have retrospectively evaluated the outcome of patients with HER-2-positive locally advanced or metastatic breast cancer who continued trastuzumab beyond disease progression, treated in their unit. [Br J Cancer] |